Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hobart L. Rogers
Observed names:
Hobart L Rogers,
Hobart Rogers
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
University of Maryland, Baltimore,
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0000-0001-5352-1270
Observed ORCID:
0000-0001-5352-1270
OpenAlex ID:
A5036876946
The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial
2017
·
Anthony G. Durmowicz
, Robert Lim
, et al.
·
Annals of the American Thoracic Society
·
152
A Randomized, Controlled Trial of the Renal Effects of Ultrafiltration as Compared to Furosemide in Patients With Acute Decompensated Heart Failure
2008
·
Hobart L. Rogers
, Joanne Marshall
, et al.
·
Journal of Cardiac Failure
·
111
Clinical Pharmacology of RNA Interference–Based Therapeutics: A Summary Based on Food and Drug Administration–Approved Small Interfering RNAs
2022
·
Xing Jing
, Vikram Arya
, et al.
·
Drug Metabolism and Disposition
·
66
PDF
CYP2D6 Genotype Information to Guide Pimozide Treatment in Adult and Pediatric Patients: Basis for the US Food and Drug Administration’s New Dosing Recommendations
2012
·
Hobart L. Rogers
, Atul Bhattaram
, et al.
·
The Journal of Clinical Psychiatry
·
52
Consistency of Drug–Drug and Gene–Drug Interaction Information in US FDA-Approved Drug Labels
2013
·
Daniela J Conrado
, Hobart L Rogers
, et al.
·
Pharmacogenomics
·
41
Allopurinol Pharmacogenetics: Assessment of Potential Clinical Usefulness
2011
·
Issam Zineh
, Padmaja Mummaneni
, et al.
·
Pharmacogenomics
·
39
Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012 and 2018
2020
·
Hobart Rogers
, Oluseyi Adeniyi
, et al.
·
Clinical and Translational Science
·
29
PDF
Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs
2022
·
Scott P. Henry
, Cecilia Arfvidsson
, et al.
·
Nucleic Acid Therapeutics
·
27
Considerations for Developing Targeted Therapies in Low‐Frequency Molecular Subsets of a Disease
2018
·
Robert N. Schuck
, Janet Woodcock
, et al.
·
Clinical Pharmacology & Therapeutics
·
24
Association of genetic mutations and loss of ambulation in childhood‐onset dystrophinopathy
2020
·
Gregory Haber
, Kristin M. Conway
, et al.
·
Muscle & Nerve
·
21
How Informative Are Drug‐Drug Interactions of Gene‐Drug Interactions?
2016
·
Chakradhar V. Lagishetty
, Jiexin Deng
, et al.
·
The Journal of Clinical Pharmacology
·
13
An Evaluation of First-in-Human Studies for RNA Oligonucleotides
2024
·
Sydney Stern
, Ronald L. Wange
, et al.
·
Nucleic Acid Therapeutics
·
9
PDF
Clinical and regulatory considerations in pharmacogenetic testing
2016
·
Robert N. Schuck
, Elizabeth Marek
, et al.
·
American Journal of Health-System Pharmacy
·
9
Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products
2026
·
Jennifer K. Lee
, Ha-Na Lee
, et al.
·
The AAPS Journal
·
1
PDF
An integrated clinical pharmacology approach for deriving dosing recommendations in a regulatory setting: Review of recent cases in psychiatry drugs
2013
·
Islam R. Younis
, Hobart Rogers
, et al.
·
The Journal of Clinical Pharmacology
UNLOAD Response to Letter to the Editor
2008
·
Stephen S. Gottlieb
, Hobart L. Rogers
·
Journal of Cardiac Failure
A Randomized, Controlled Trail of the Renal Effects of Ultrafiltration as Compared to Furosemide
2007
·
Hobart Rogers
, Joanne Marshall
, et al.
·
Journal of Cardiac Failure
PDF
Show more works
View as search
Works count:
17
Citation count:
594
H-index:
11
I10-index:
11
Year
Topic
Type